CBC Group
CBC hits second close on China life science real assets fund
Specialist healthcare investor CBC Group has reached a second close on its China-focused life science real assets fund with USD 875m in commitments.
Innovation can end China's healthcare downcycle - AVCJ Forum
Investors in Chinese healthcare are looking for innovators with global competencies to lead an industry recovery following a challenging past 12 months, the AVCJ Private Equity & Venture Forum China 2023 heard.
The innovation game: China GPs play safe
China investors have abandoned their previous high-risk-high-return approach in favour of proven business models and profitability. Hotspots like autonomous driving, biotech, and SaaS are no exception
Healthcare specialist CBC adds managing director
Asia healthcare investor CBC Group has appointed Billy Cho, formerly CFO of listed Chinese drug developer Zai Lab, as a senior managing director for private equity.
PE-backed Lu Daopei Medical files for Hong Kong IPO
Lu Daopei Medical Group Holding, which runs a network of hospitals in China that specialise in the treatment of blood diseases, has filed for a Hong Kong IPO.
China: Who’s investing?
Private equity investment in China remains in the doldrums yet local investors claim to see green shoots. Where, when, and how they engage with the market is likely to differ from previous cycles
Eight Roads leads $38m round for China biotech player Adcentrx
China and US-based biotech company Adcentrx has raised USD38m in an extended Series A round led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, and Trinity Innovation Fund.
Deal focus: CBC gets counterintuitive in China
CBC Group has helped multiple start-ups move from in-licensing to drug development to commercialisation. With China’s Hasten, it is navigating this tried-and-tested journey in reverse
CBC, Mubadala lead $315m round for China's Hasten Biopharma
Specialist healthcare investor CBC Group and Mubadala Investment have led a USD 315m round for China-based Hasten Biopharmaceutic, with participation from other undisclosed institutional investors.
Portfolio: CBC Group and Ensem Therapeutics
CBC Group plans to allocate USD 300m from its latest flagship fund to a biotech incubation platform. Artificial intelligence-enabled drug discovery player Ensem Therapeutics is an example of what it wants to achieve.
China biotech: End of the boom
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
AstraZeneca-CICC fund backs China gene sequencer
Axbio, a China-based provider of gene sequencing and diagnostic systems, has raised nearly USD 100m in Series B funding led by AstraZeneca-CICC Healthcare Industrial Fund and Yunfeng Capital.
Singapore mRNA vaccine developer raises $140m
RVAC Medicines, a Singapore-based company involved in developing messenger RNA (mRNA) vaccines for COVID-19, has closed a Series B round that takes its overall funding to USD 140m.
CBC strikes China's first royalty-based biomedicine deal
R-Bridge Fund, a credit vehicle established by healthcare-focused private equity firm CBC Group, has completed what it claims is the first royalty-backed investment in China’s biomedicine space.
CBC, APG launch China healthcare infra fund
Specialist healthcare investor CBC Group has teamed up with APG Asset Management to launch a $1.5 billion fund dedicated to the development of healthcare infrastructure in China.
China biotech: Going global
A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
CBC-led consortium buys Bain's stake in Korean botox maker
A consortium led by Asia healthcare-focused private equity firm CBC Group has agreed to acquire a 46.9% interest in Hugel, a South Korean manufacturer of botox and other health-related pharmaceuticals, for KRW1.7 trillion ($1.5 billion).
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
CBC Group founder backs healthcare-focused SPAC
Wei Fu, the founder and CEO of Asia-focused healthcare investor CBC Group, has launched a special purpose acquisition company (SPAC) to pursue deals in the sector.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
Everest Medicines soars on debut after $451m IPO
Everest Medicines, a Chinese biotech start-up backed by CBC Group, performed strongly in early trading in Hong Kong following a HK$3.5 billion ($451 million) IPO.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.